High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis
Current Oncology · 27.04.2026 · 33 (5) · 249
DOI: 10.3390/curroncol33050249 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Current Oncology, online erschienen am 27.04.2026. Verfasst von Carmel Awadallah und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, St John Episcopal Hospital, Far Rockaway, NY 11691, USA. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
High-risk cytogenetic multiple myeloma (HRMM) confers inferior outcomes despite significant therapeutic advances. Real-world data characterizing contemporary treatment patterns across lines of therapy in this population are limited.
Methods
We conducted a multicenter retrospective study of 205 patients with HRMM diagnosed between January 2009 and January 2024. High-risk cytogenetics were defined according to the International Myeloma Working Group (IMWG) and Revised International Staging System (R-ISS) criteria as the presence of del(17p), t(4;14), t(14;16), t(14;20), and/or gain/amplification of 1q21. Treatment regimens were categorized by the number of agents (doublet, triplet, quadruplet), mechanism of action (proteasome inhibitor [PI]-based, immunomodulatory drug [IMiD]-based, and anti-CD38 monoclonal antibody-based), and specific regimen composition. Treatment patterns were analyzed across three treatment eras and stratified by age (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Internal Medicine, St John Episcopal Hospital, Far Rockaway, NY 11691, USA.
- Department of Internal Medicine, Hamad Medical Corporation, Doha 3050, Qatar.
- Levine Cancer Center, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28204, USA.
- Division of Hematology and Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
- Division of Hematology and Oncology, University of Cincinnati, Cincinnati, OH 45219, USA.
- Division of Hematology and Bone Marrow Transplant, Alleghany Medical Center, Pittsburg, PA 15212, USA.
ORCID-Profile: Anas Zayad, Shebli Atrash, Anita Mazloom, Omar Alkharabsheh, Prerna Mewawalla, Forat Lutfi, Zahra Mahmoudjafari, Jeries Kort, Al-Ola Abdallah
Zitieren
APA
Awadallah, C., Zayad, A., Atrash, S., Mazloom, A., Alkharabsheh, O., Mewawalla, P., Shah, M. R., Lutfi, F., Mahmoudjafari, Z., Umair Mushtaq, M., Kort, J., Habib, A., & Abdallah, A. O. (2026). High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis. Current Oncology, 33(5), 249. https://doi.org/10.3390/curroncol33050249
Vancouver
Awadallah C, Zayad A, Atrash S, Mazloom A, Alkharabsheh O, Mewawalla P, et al. High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis. Current Oncology. 2026;33(5):249. doi:10.3390/curroncol33050249
BibTeX
@article{Awadallah2026,
author = {Awadallah, Carmel and Zayad, Anas and Atrash, Shebli and Mazloom, Anita and Alkharabsheh, Omar and Mewawalla, Prerna and Shah, Mansi R and Lutfi, Forat and Mahmoudjafari, Zahra and Umair Mushtaq, Muhammad and Kort, Jeries and Habib, Alma and Abdallah, Al-Ola},
title = {High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {5},
pages = {249},
doi = {10.3390/curroncol33050249}
}
EUVIMED